Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)
ConclusionsThe outcome of patients treated with the JN-H-07 protocol showed improvement over the results reported by previous studies conducted in Japan. Molecular and genetic profiling may enable a more precise stratification of the high-risk cohort.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Childhood Cancer | Children | Clinical Trials | Genetics | Japan Health | Neuroblastoma | Neurology | Neurosurgery | Stem Cell Therapy | Stem Cells | Study | Toxicology